Catalyst Biosciences, Inc. (CBIO)
| Market Cap | 45.01M |
| Revenue (ttm) | 6.67M |
| Net Income (ttm) | -80.03M |
| Shares Out | 31.48M |
| EPS (ttm) | -2.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 30,777,057 |
| Open | 1.23 |
| Previous Close | 1.34 |
| Day's Range | 1.20 - 1.52 |
| 52-Week Range | 0.35 - 5.20 |
| Beta | 2.02 |
| Analysts | Buy |
| Price Target | 11.56 (+708.4%) |
| Earnings Date | May 9, 2022 |
About CBIO
Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system. It develops CB 2782-PEG, a component 3 (C3) degrader for the treatment of dry age-related macular degeneration (dAMD); and CB 4332 for patients with deficiencies in complement factor I (CFI), including dAMD. The compan...
Financial Performance
In 2021, CBIO's revenue was $7.34 million, a decrease of -64.97% compared to the previous year's $20.95 million. Losses were -$87.93 million, 56.4% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for CBIO stock is "Buy." The 12-month stock price forecast is 11.56, which is an increase of 708.39% from the latest price.
News
Hot Penny Stocks to Buy This Week? 3 to Watch
Which penny stocks are you watching right now? The post Hot Penny Stocks to Buy This Week?
Penny Stocks To Buy Now? 3 With Unusual Options Activity To Watch
Penny stocks with unusual options activity today. The post Penny Stocks To Buy Now?
Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
Catalyst Biosciences (CBIO) stock is rocketing higher on Monday after announcing the sale of its protease medicines portfolio. The post Why Is Catalyst Biosciences (CBIO) Stock Soaring 170% Today?
Why Catalyst Biosciences Shares Are Skyrocketing Today
Catalyst Biosciences Inc (NASDAQ: CBIO) shares are trading higher by 180.26% at $1.06 after the company announced it sold its complement portfolio for $60 million. A definitive asset purchase and sale a...
Catalyst Biosciences Stock More Than Doubles After Assets Sale To Vertex
Catalyst Biosciences Inc (NASDAQ: CBIO) has agreed to sell its portfolio of protease medicines that regulate complement to Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) for $60 million. "This sale ...
Penny Stocks To Buy Now? 4 To Watch Under $1
Penny stocks under $1 to watch right now. The post Penny Stocks To Buy Now?
Catalyst Biosciences Sells Complement Portfolio for $60 Million
SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that it has signed a definitive asset purchase and sale agreement with Vertex Phar...
Catalyst Biosciences Reports First Quarter 2022 Operating & Financial Results
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the first quarter ended March 31, 2022.
Catalyst Biosciences Reports Fourth Quarter and Year-end 2021 Operating & Financial Results and Provides a Corporate ...
SOUTH SAN FRANCISCO, Calif., March 31, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the fourth quarter and year ended Decemb...
Catalyst Biosciences Regains Rights to CB 2782-PEG for the Treatment of Dry AMD Expands CBIO's Complement Portfolio i...
SOUTH SAN FRANCISCO, Calif., March 15, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the company has regained full rights to CB 2782-PEG, a C3-degrader for the ...
Catalyst Biosciences Engages Perella Weinberg Partners to Assist the Company in Exploring Strategic Alternatives
SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced it has retained Perella Weinberg Partners (PWP) as a financial advisor to assist ...
Catalyst Biosciences Receives Rare Pediatric Disease Designation for CB 4332 for the Treatment of CFI Deficiency
SOUTH SAN FRANCISCO, Calif., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease De...
Catalyst Biosciences, Inc. (CBIO) Upgraded to Buy: Here's What You Should Know
Catalyst Biosciences, Inc. (CBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Catalyst Biosciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that members of its executive management team will participate in a fireside chat...
What Is Happening With Catalyst Biosciences Shares Today?
Catalyst Biosciences Inc (NASDAQ: CBIO) has decided to halt the clinical development of MarzAA (engineered FVIIa) and focus solely on complement programs and protease medicines platforms. MarzAA was und...
Catalyst Biosciences Announces Change in Corporate Strategy
Reports Third Quarter 2021 Operating & Financial Results Reports Third Quarter 2021 Operating & Financial Results
Catalyst Biosciences Announces CFI Variant Presentations at Two Upcoming Scientific Conferences
SOUTH SAN FRANCISCO, Calif., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that Grant Blouse, Ph.D., chief scientific officer, will present at two upcoming ...
Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Catalyst Biosciences, Inc. (CBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Catalyst Biosciences Announces Chief Financial Officer Transition
SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that its chief financial officer, Clinton Musil, has resigned for personal reason...
Catalyst Biosciences' Lead Candidate Secures Orphan Drug Tag For Blood Clotting Disorder
The FDA has granted Orphan Drug Disease Designation to Catalyst Biosciences Inc's (NASDAQ: CBIO) Marzeptacog alfa (activated), or MarzAA, for Factor VII Deficiency (FVIID). Factor VII deficiency is a b...
FDA Grants Catalyst Biosciences Orphan Drug Designation for MarzAA for the Treatment of Factor VII Deficiency
SOUTH SAN FRANCISCO, Calif., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Disease...
Catalyst Biosciences to Present at the Cantor Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced that a fireside chat including members of its executive management team will be ...
Catalyst Biosciences, Inc. (CBIO) Reports Q2 Loss, Tops Revenue Estimates
Catalyst Biosciences, Inc. (CBIO) delivered earnings and revenue surprises of 5.88% and 13.20%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Catalyst Biosciences Reports Second Quarter 2021 Operating & Financial Results and Provides a Corporate Update
SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced its operating and financial results for the second quarter ended June 30, 2021, a...
Catalyst Biosciences, Inc. (CBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Catalyst Biosciences, Inc. (CBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.